← Leaderboards
Adam David Durbin
St. Jude Children'S Research Hospital
$2,744,766
Attributed
$3,257,241
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,257,241 · 3
By mechanism
K08$1,282,920 · 1
R37$1,205,608 · 1
R01$768,713 · 1
Top collaborators
- Brian Abraham1 shared
- Jun Qi1 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Michael A Dyer$24,988,379
- Paul Northcott$7,792,208
- Richard James Gilbertson$38,555,720
- Claudia Andrea Benavente$3,328,001
- James R Downing$3,840,185
Others in their field
Other Emerging Leaders on “Transcription Factor”
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
- Adam David Hoppe · South Dakota State University$9,046,059
- Jason Daniel Buenrostro · Broad Institute, Inc.$8,375,564
- Frederic Geissmann · Sloan-Kettering Inst Can Research$7,224,019
- Carl Wu · Johns Hopkins University$7,122,467
- Stacy Andersen · Boston Medical Center$7,032,657
Research focus
Transcription FactorChildPublic HealthMutationNeuroblastoma CellTumorNeoplastic CellNovel StrategiesMalignant NeoplasmsMissionInnovationNeuroblastomaIn VivoIn VitroCellsMalignant Childhood NeoplasmChemotherapyChildhoodEpigenomicsHigh RiskGenetic TranscriptionGenesAnimal ModelLaboratories
Grant awards (8)
Targeting EP300 epigenomic control in neuroblastoma$768,713
R01 · FY2025 · CA · contact PI
Dissecting high-risk cell states in neuroblastoma$592,554
R37 · FY2025 · CA · contact PI
Dissecting high-risk cell states in neuroblastoma$613,054
R37 · FY2024 · CA · contact PI
Targeting EP300, a selective dependency in neuroblastoma$195,480
K08 · FY2024 · CA · contact PI
Targeting EP300, a selective dependency in neuroblastoma$272,282
K08 · FY2023 · CA · contact PI
Targeting EP300, a selective dependency in neuroblastoma$272,282
K08 · FY2022 · CA · contact PI
Targeting EP300, a selective dependency in neuroblastoma$271,802
K08 · FY2021 · CA · contact PI
Targeting EP300, a selective dependency in neuroblastoma$271,074
K08 · FY2020 · CA · contact PI